



		ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 09/019,441			
		APPLICANT Mitchell E. REFF et al					
		FILING DATE February 5, 1998		GROUP 1642			
PTO-1449							
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
MO	5,648,260	7/15/97	Winter et al	—	—		
MO	5,635,600	6/3/97	Fanger et al	—	—		
MO	5,585,089	12/17/96	Queen et al	—	—		
MO	5,543,144	8/6/96	Chang	—	—		
MO	5,348,876	9/20/94	Michaelsen et al	—	—		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
MO	WO 88/06891	9/22/88	PCT	—	—		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Sarfati et al, "Native and recombinant soluble CD23 fragments with IgE suppressive activity" Immunol., 76:662-667, 1992							
MO	Pène et al, "Interleukin 5 enhances interleukin 4-induced IgE production of normal human B cells...", Eur. J. Immunol., 18:929-935, 1988						
MO	Sarfati et al, "In vitro synthesis of IgE by human lymphocytes", Immunol., 53:197-205 1984						
MO	Saxon et al, "Inhibition of human IgE production via FcεR-II stimulation results from a decrease in the mRNA for secreted ...chains", J. Immunol., 147(11):4000-4006, 1991						
MO	Sherr et al, "Binding the low affinity FcεR on B cells suppresses ongoing human IgE Synthesis", J. Immunol., 142(2):481,489, 1989						
MO	Bonnefoy et al, "A new role for CD23 in inflammation", Immunol. Today, 17(9):418-420, 1996						
MO	Bonnefoy et al, "Inhibition of human interleukin 4-induced IgE synthesis by a subset of anti-CD23/FcεRII monoclonal antibodies", Eur. J. Immunol., 20:139-144, 1990						
MO	Angal et al, "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) Antibody", Mol. Immunol. 30(1):105-108, 1993						
MO	Urlaub et al, "Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions" Somatic Cell and Mol. Genetics, 12(6):555-566, 1986						
MO	D'Ambrosio et al, "Recruitment and Activation of PTP1C in Negative Regulation of Antigen Receptor Signaling by FcγRIIB1, Science, 268:293-297, 1995						
MO	Man Sung Co et al, "Humanized anti-lewis Y antibodies: in vitro properties and pharmacokinetics in Rhesus monkeys", Can. Res., 56:1118-1125, 1996						
MO	Ono et al, "Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling", Cell, 90:293-301, 1997						
EXAMINER			DATE CONSIDERED				
Marianne Dijk			9/16/99				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 09/019,411
	APPLICANT Mitchell E. REFF et al		
	FILING DATE February 5, 1998	GROUP 1642	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
NO	Parren et al, "Characterization of IgG FcR-Mediated proliferation of human T cells induced by mouse and human anti-CD3 ^{monoclonal} antibodies", J. Immunol., 148(3):695-701, 1992		
NO	Steplewski et al, "Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies ^{with anti-human} specificity", Proc. Natl. Acad. Sci., 85(13):4852-4856, 1988		
NO	Lund et al, "Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG ⁴ ", J. Immunol., 147(8):2657-2662, 1991		
NO	Man Sung Co et al, "Chimeric and humanized antibodies with specificity for the CD33 antigen", J. Immunol., 148(3):1149-1154, 1992		
NO	Parren et al, "Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 ^{monoclonal} antibodies", J. Immunol., 148(3):695-701, 1992		
NO	Wakai et al, "Anti-CD23 monoclonal antibodies: comparisons of epitope specificities and modulating capacities for...production", Hybridoma, 12(1):25-43, 1993		
NO	Shakib et al, "A study of the interrelationship between circulating IgG subclass anti-IgE autoantibodies, IgE and...asthma", Allergol. et Immunopathol., 21(1):20-24, 1993		
NO	Spiegelberg, "Fc Receptors for IgE and Interleukin-4 induced IgE and IgG4 Secretion", J. Invest. Dermatol., 94(6):49S-52S, 1990		
NO	Maliszewski, "Induction of B cell activities by interleukin 4 is inhibited by a receptor-specific monoclonal antibody in vitro", Eur. J. Immunol., 20:1735-1740, 1990		
NO	Yanagihara et al, "Suppression of IgE production by IPD-1151T (Suplatast Tosilate), a new dimethylsulfonium agent: (1) regulation...response", Japan J. Pharmacol., 61:23-30 (1993)		
NO	Hjulström, "No role of interleukin-4 in CD23/IgE-mediated enhancement of the murine antibody response in vivo", Eur. J. Immunol., 25:1469-1472, 1995		
NO	Escura et al, "Regulation and targeting of T-cell immune responses by IgE and IgG antibodies", Immunol., 86:343-350, (1995)		
NO	Bonnefoy et al, "Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE", J. Immunol., 138:2970-2978, 1987		
NO	Gustavsson et al, "CD23/IgE-mediated regulation of the specific antibody response in vivo", J. Immunol., 152(10):4793-4800, 1994		
NO	Yanigihara et al, "Establishment of sensitive radioimmunoassay for the detection of human IgE-binding factor (soluble CD23), Int. Arch. of Allergy Immunol., 98:189-199, 1992		
NO	Flores-Romo et al, "Inhibition of an in vivo antigen-specific IgE response to antibodies to CD23", Science, 261:1038-1041, 1993		
NO	Luo et al, "Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation", 146(7):2122-2129, 1991		
NO	Pène et al, "IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α ... E ₂ ", Proc. Natl. Acad. Sci., 85:6880-6884, 1988		
NO	Sarfati et al, "Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE ¹ ", J. Immunol., 141(7):2195-2199, 1988		
NO	Henchoz-Lecoanet et al, "The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4...B cells", J. Immunol., 88:35-39, 1996		
NO	Bonnefoy et al, "Receptors for IgE", Cur. Opinion in Immunol., 5:944-949, 1993		
EXAMINER			DATE CONSIDERED 7/16/99




EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 091015-4			
		APPLICANT Mitchel E. REFF et al					
		FILING DATE February 5, 1998		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
MD	Pène et al, "Modulation of IL-4-induced human IgE production in vitro by IFN-γ and IL-5: the role of soluble CD23 (s-CD23)", J. Cell. Biochem., 39:253-264 (1989)						
MD	Donnefoy et al, "Regulation of IgE synthesis by CD23/CD21 interaction", Int. Arch. Allergy Immunol., 107:40-42, 1995						
MD	Aubry et al, "CD21 is a ligand for CD23 and regulates IgE production", Nature, 358:505-507, 1992						
MD	Grosjean et al, "CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell...clones", Eur. J. Immunol., 24:2982-2986, 1994						
MD	Nambu et al, "Functional significance of CD23- on CD23-transfected Th2 clone", Immunol. Letters, 44:163-167, 1995						
MD	Burton et al, "Human Antibody Effector Function", Adv. Immunol., 51:1-84, 1992						
EXAMINER			DATE CONSIDERED				
			9/16/99				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION				ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 09/019,441	
PTO-1449				APPLICANT Mitchell E. Reff et al.		FILING DATE February 5, 1998	
U.S. PATENT DOCUMENTS				GROUP 1642			
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
MD	4,940,782	07/10/90	Rup et al.	—	—		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	WO 89/00138	01/12/89	International	—	—		
	WO 96/12741	05/02/96	International	—	—		
MD	WO 87/07302	12/03/87	International WO	—	—		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Rector et al., Immunol., 55: 481-488 (1985)						
	Seumura et al., J. Immunol., 137: 1214-1220 (1986)						
	Noro et al., J. Immunol., 137: 1258-1263 (1986)						
MD	Bonney et al., J. Immunol., 138: 2970-2978 (1987)						
MD	Flores-Romo et al., Science, 261: 1038-1046 (1993)						
MD	Sherr et al., J. Immunol., 142: 481-489 (1989)						
MD	Pene et al., Proc. Natl. Acad. Sci., USA, 85: 6880-6884 (1988)						
MD	Bonney et al., Eur. J. Immunol 20: 139-144 (1990)						
MD	Sarfaty et al., J. Immunol 141: 2195-2199 (1988)						
MD	Wakai et al., Hybridoma 12: 25-43 (1993)						
	Yu et al., Nature 369: 753-756 (1994)						
EXAMINER				DATE CONSIDERED			
Marianne Dubois				9/16/99			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p align="center">INFORMATION DISCLOSURE CITATION</p> <p align="center">PTO-1449</p>		ATTORNEY'S DKT NO. 012712-353		APPLICATION NO. 08/803,085		
		APPLICANT Mitchell E. Reff et al.				
		FILING DATE February 20, 1997		GROUP ART UNIT 1642		
		U.S. PATENT DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
MO	Saxon et al., J. Immunol., 147: 4000-4006 (1991)					
MO	D'Ambrosio et al., Science, 268: 293-297 (1995) RECEIVED					
MO	Leconant et al., Immunol., 88: 35-39 (1996) JUL 08 1998					
	Bonnefoy et al., Int. Amer. Allergy Immunol., 107: 40-42 (1995) MAIL ROOM SERVICE CENTER					
MO	Aubry et al., Nature, 358: 505-507 (1992)					
	Aubry et al., Immunol., 5: 944-949 (1993)					
	Bonnefoy et al., Curr. Opin. Eur. J. Immunol., 24: 2982-2988 (1994)					
MO	Nambu et al., Immunol. Lett., 44: 163-167 (1995)					
MO	Sarfati et al., Immunol., 53: 197-205 (1984)					
MO	Pene et al., J. Cell Biochem., 39: 253-269 (1989)					
	Pene et al., J. Immunol., 18: 929-935 (1988)					
EXAMINER			DATE CONSIDERED			
						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT NO. 012712-353		APPLICATION NO. 08/803,085	
				APPLICANT Mitchell E. Reff et al.			
FILING DATE February 20, 1997				GROUP ART UNIT 1642			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Saxon et al., J. Clin. Immunol. Allergy, 86 (3 pt 1) 333-344 (1990)						
	Sarfati et al., Immunol., 76: 662-667 (1992)						
	Angal et al., Mol. Immunol., 30: 105-108 (1993)						
	Hassner and Saxon, J. Immunol., 132: 2844 (1984)						
	Carroll et al., J. Immunol. Methods 89: 61 (1986)						
	Boerner et al., J. Immunol., 147: 86 (1991)						
EXAMINER	<i>Marianne D.B.</i>			DATE CONSIDERED 7/16/93			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.